BioPharma Accord, Inc. reports the U.S. FDA has greenlit their application for a license regarding their proposed biosimilar to STELARA®, named DMB-3115.

Innate Pharma has been given the green light by the FDA to resume its Lacutamab Clinical Program after the previous partial clinical hold was removed.

Avenzo Therapeutics has disclosed the promising clinical phase CDK2 inhibitor known as AVZO-021, originally developed by Allorion Therapeutics.

Inspirna teams up with German-based Merck KGaA to expedite the worldwide advancement of the drug Ompenaclid, known as RGX-202

Debiopharm is collaborating with Repare Therapeutics to investigate combining PKMYT1 and WEE1 inhibitors as a potential cancer treatment strategy.

KYV-101, a therapeutic agent by Kyverna, has been granted approval by the American FDA for use in a Phase 2 study, KYSA-7, targeting individuals suffering from advanced, treatment-resistant Multiple Sclerosis.

GPN Vaccines Announces Encouraging Safety and Immunogenic Response Results in Initial Phase Trial of its Gamma-PN Vaccine.

Bayer AG and its independent subsidiary Asklepios BioPharmaceutical, Inc., focused on gene therapy, have completed data collection for the AB-1005 (AAV2-GDNF) Phase Ib trial after 18 months.

Genascence Corporation has launched a Phase 1b clinical study to evaluate the efficacy of their gene treatment, codenamed GNSC-001, targeting knee osteoarthritis.

Upstream Bio has initiated the first patient treatments in a Phase II study on Verekitug (UPB-101) targeting Chronic Rhinosinusitis with Nasal Polyps.

Ventus Therapeutics has begun trials on VENT-03, an oral drug designed to block cGAS, marking a pioneering approach in this category.

Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).